BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32690948)

  • 21. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Hankey W; Chen Z; Wang Q
    Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 24. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
    Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C
    Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Cancer Progression and the Epigenome.
    Arap W; Pasqualini R; Costello JF
    N Engl J Med; 2020 Dec; 383(23):2287-2290. PubMed ID: 33264551
    [No Abstract]   [Full Text] [Related]  

  • 27. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
    Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
    PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus.
    Zhang X; Cowper-Sal lari R; Bailey SD; Moore JH; Lupien M
    Genome Res; 2012 Aug; 22(8):1437-46. PubMed ID: 22665440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
    Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
    Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXA1: a transcription factor with parallel functions in development and cancer.
    Bernardo GM; Keri RA
    Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes.
    Gao N; Zhang J; Rao MA; Case TC; Mirosevich J; Wang Y; Jin R; Gupta A; Rennie PS; Matusik RJ
    Mol Endocrinol; 2003 Aug; 17(8):1484-507. PubMed ID: 12750453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
    Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
    Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA.
    Wang D; Garcia-Bassets I; Benner C; Li W; Su X; Zhou Y; Qiu J; Liu W; Kaikkonen MU; Ohgi KA; Glass CK; Rosenfeld MG; Fu XD
    Nature; 2011 May; 474(7351):390-4. PubMed ID: 21572438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Cheng Y; Wang D; Jiang J; Huang W; Li D; Luo J; Gu W; Mo W; Wang C; Li Y; Gu S; Xu Y
    Prostate; 2020 May; 80(8):640-652. PubMed ID: 32282098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
    Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
    Elife; 2019 Dec; 8():. PubMed ID: 31855178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.